Lenalidomide-induced hand-foot syndrome: A case report

Authors

  • Tarinee Sasiprapa Dermatology department, Phramongkutklao hospital
  • Julphat Intarasupht Division of Dermatology, Department of Medicine, Phramongkutklao Hospital, Ratchathewi, Bangkok, Thailand

Keywords:

Hand-foot syndrome, palmoplantar erythrodysesthesia, chemotherapy-induced acral erythema, lenalidomide

Abstract

Hand-foot syndrome (HFS, palmoplantar erythrodysesthesia, chemotherapy-induced acral erythema) is a reaction which occurs after administration of systemic medications especially chemotherapeutic drugs. The usual clinical presentations include erythema, edema and a burning pain on the palms and soles. To the best of our knowledge, hand-foot syndrome caused by lenalidomide has never been reported.

We reported a case of a 57 year-old Thai woman with multiple painful edematous papules on her palms and soles after receiving lenalidomide in the treatment of relapsed and refractory multiple myeloma. The clinical and histopathologic findings are compatible with hand-foot syndrome. She was diagnosed with lenalidomide-induced hand-foot syndrome and treated with topical steroid and dose reduction of lenalidomide. The resolution of disease was observed at a 3-week follow-up visit.

References

Braghiroli CS, Leiri R, Ocanha JP, Paschoalini RB, Miot HA. Do you know this syndrome? Hand-foot syndrome. Bras Dermatol 2017; 92: 131-3.

Sviggum HP, Davis MDP, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006; 142:1298-302.

Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974;148: 90–2.

Degen A, Alter M, Schenck F, et al. The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol 2010; 8:652-61.

Sanghi S, Grewal RS, Vasudevan B, Nagure A. Capecitabine induced Hand-Foot Syndrome: Report of two cases. Med J Armed Forces India 2013; 69:65‐7.

Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71:787-94.

Mar tschick A, Sehouli J, Patzelt A, et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 2009; 29:2307-13.

Imbesi S, Allegra A, Calapai G, Musolino C, Gangemi S. Cutaneous adverse reactions to lenalidomide. Allergol Immunopathol 2015; 43: 88-91.

Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Ann Oncol 2007; 18: 1159–64.

Nagore E, Insa A, Sanmartín O. Anti-neoplastic therapy-induced palmarplantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225–34.

Downloads

Published

2019-12-27

How to Cite

Sasiprapa, T., & Intarasupht, J. (2019). Lenalidomide-induced hand-foot syndrome: A case report. Thai Journal of Dermatology, 35(4), 193–197. Retrieved from https://he02.tci-thaijo.org/index.php/TJD/article/view/208008

Issue

Vol. 35 No. 4 (2019): October - December

Section

Case Report

License

เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ

บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น